99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer

Bioconjugate Chemistry

Volumn 19, Issue 6, 2008, Pages 1170-1178

  Shi, Jiyun ^a   Jia, Bing ^a   Liu, Zhaofei ^a   Yang, Zhi ^b   Yu, Zilin ^a   Chen, Kai ^c   Chen, Xiaoyuan ^c   Liu, Shuang ^d   Wang, Fan ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BODY FLUIDS; COMPLEXATION; COUPLING AGENTS; DISEASES; MAMMALS; RADIATION; RADIOACTIVITY;

COLON CANCER; GASTROINTESTINAL TRACT; HUMAN COLON CANCER; NUDE MICE; PEPTIDE RECEPTOR; POST INJECTION; PROPERTY; SPECT IMAGING; TRIPHENYL PHOSPHINES; TUMOR IMAGING;

TUMORS;

(6 HYDRAZINONICOTINIC ACID BOMBESIN [7-14]AMIDE)(TRICINE)(TRISODIUM TRIPHENYLPHOSPHINE 3,3'3'' TRISUFORATE) TC 99M; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; BOMBESIN; CROSS LINKING REAGENT; DIAGNOSTIC AGENT; GASTRIN RELEASING PEPTIDE; LIGAND; NICOTINIC ACID; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CANCER; DRUG ACCUMULATION; FEMALE; HYDROPHILICITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CELL STRAIN HT29; CHEMISTRY; COLON TUMOR; HUMAN; KINETICS; METABOLISM; METHODOLOGY; RADIOCHEMISTRY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; XENOGRAFT;

MUS MUSCULUS;

AMINO ACID SEQUENCE; ANIMALS; BOMBESIN; COLONIC NEOPLASMS; CROSS-LINKING REAGENTS; GASTRIN-RELEASING PEPTIDE; HT29 CELLS; HUMANS; KINETICS; LIGANDS; MICE; MICE, INBRED BALB C; NIACIN; ORGANOTECHNETIUM COMPOUNDS; RADIOCHEMISTRY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

EID: 45749108311     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700471z     Document Type: Article

References (62)

1. Erspamer, V., Erpamer, G. F., and Inselvini, M. (1970) Some pharmacological actions of alytesin and bombesin. J. Pharm. Pharmacol. 22, 875-876.
2. Prasad, S., Mathur, A., Gupta, N., Jaggi, M., and Singh, A. T. (2007) Bombesin analogs containing α-amino-isobutyric acid with potent anticancer activity. J. Pept. Sci. 13, 54-62.
3. Ohki-Hamazaki, H., Iwabuchi, M., and Maekawa, F. (2005) Development and function of bombesin-like peptides and their receptors. Int. J. Dev. Biol. 49, 293-300.
4. Patel, O., Shulkes, A., and Baldwin, G. S. (2006) Gastrin-releasing peptide and cancer. Biochim. Biophys. Acta 1766, 23-41.
5. Nakagawa, T., Hocart, S. J., Schumann, M., Tapia, J. A., Mantey, S. A., Coy, D. H., Tokita, K., Katsuno, T., and Jensen, R. T. (2005) Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP). Biochem. Pharmacol. 69, 579-593.
6. Moody, T. W., Carney, D. N., Cuttitta, F., Quattrocchi, K., and Minna, J. D. (1985) High affinity receptors for bombesin/ GRP-like peptides on human small cell lung cancer. Life Sci. 37, 105-113.
7. Radulovic, S. S., Milovanovic, S. R., Cai, R. Z., and Schally, A. V. (1992) The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc. Soc. Exp. Biol. Med. 200, 394-401.
8. Carroll, R. E., Matkowskyj, K. A., Chakrabarti, S., McDonald, T. J., and Benya, R. V. (1999) Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am. J. Physiol. 276, G655-G665.
9. 1. Cancer Res. 59, 962-967.
10. Carroll, R. E., Ostrovskiy, D., Lee, S., Danilkovich, A., and Benya, R. V. (2000) Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol. Pharmacol. 58, 601-607.
11. Saurin, J. C., Fallavier, M., Sordat, B., Gevrey, J. C., Chayvialle, J. A., and Abello, J. (2002) Bombesin stimulates invasion and migration of isrecol colon carcinoma cells in a Rho-dependent manner. Cancer Res. 62, 4829-4835.
12. Cassano, G., Resta, N., Gasparre, G., Lippe, C., and Guanti, G. (2001) The proliferative response of HT-29 human colon adenocarcinoma cells to bombesin-like peptides. Cancer Lett. 172, 151-157.
13. Varvarigou, A., Bouziotis, P., Zikos, C., Scopinaro, F., and De Vincentis, G. (2004) Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother. Radiopharm. 19, 219-229.
14. Reubi, J. C. (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389-427.
15. Jong, M., Kwekkeboom, D., Valkema, R., and Krenning, E. P. (2003) Radiolabelled peptides for tumour therapy: Current status and future directions. Eur. J. Nucl. Med. 30, 463-469.
16. Van de Wiele, C., Dumont, F., van Belle, S., Slegers, G., Peers, S. H., and Dierckx, R. A. (2001) Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? Nucl. Med. Commun. 22, 5-15.
17. Hoffman, T. J., Quinn, T. P., and Volkert, W. A. (2001) Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl. Med. Biol. 28, 527-539.
18. 4] bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer. 83, 657-663.
19. Zhang, H. W., Chen, J. H., Waldherr, C., Hinni, K., Waser, B., Reubi, J. C., and Maecke, H. R. (2004) Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 64, 6707-6715.
20. 111In labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J. Nucl. Med. 44, 823-831.
21. 2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl. Med. Biol. 30, 101-109.
22. 2. Nucl. Med. Biol. 29, 423-430.
23. 177Lu-AMBA. Eur. J. Nucl. Med. Mol. Imaging 34, 95-100.
24. 68Ga-labeled bombesin(6-14) analog. J. Nucl. Med. 46, 691-699.
25. 4)-Bombesin(1-14). Bioconjugate Chem. 18, 724-730.
26. Parry, J. J., Andrews, R., and Rogers, B. E. (2007) MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res. Treat. 101, 175-183.
27. 64Cu-labeled DOTA-Linker-Bombesin(7- 14) analogues containing different amino acid linker moiety. Bioconjugate Chem. 18, 1110-1117.
28. 64Cu Bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med. 48, 1327-1337.
29. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. U.S.A. 104, 12462-12467.
30. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol. 33, 371-380.
31. 64Cu-labeled bombesin analogue. Bioconjugate Chem. 14, 756-763.
32. 3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 45, 1390-1397.
33. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res. 23, 63-70.
34. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjugate Chem. 10, 254-260.
35. Van de Wiele, C., Dumont, F., Broecke, V. R., Oosterlinck, W., Cocquyt, V., Serreyn, R., Peers, S., Thornback, J., Slegers, G., and Dierckx, R. A. (2000) Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med. 27, 1694-1699.
36. 3 bombesin analogues. Nucl. Med. Biol. 34, 17-28.
37. 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjugate Chem. 13, 599-604.
38. Scopinaro, F., Varvarigou, A., Ussof, W., De Vincentis, G., Sourlingas, T. G., Evangelatos, G. P., Datsteris, J., and Archimandritis, S. C. (2002) Technetium labeled bombesin like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother. Radiopharm. 17, 327-335.
39. 2: an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjugate Chem. 14, 93-102.
40. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur. J. Nucl. Med. Mol. Imaging 30, 1378-1382.
41. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging 30, 247-258.
42. 99mTc-leu13-BN1). Cancer Bioth. Radiopharm. 19, 245-252.
43. 99mTc: A preclinical study. J. Med. Chem. 48, 100-110.
44. 2: radiochemical evaluation with co-ligands EDDA (EDDA = Ethylenediamine-N,N′-diacetic acid), tricine, and nicotinic acid. Synth. React. Inorg. Met.-Org. Chem. 35, 43-51.
45. Lin, K. S., Luu, A., Baidoo, K. E., Hossein, H. G., Chen, M-K., Brenneman, K., Pili, R., Pomper, M., Carducci, M. A., and Wagner, H. N., Jr. (2005) A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chem. 16, 43-50.
46. 99mTc(III) '4 + 1′ bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjugate Chem. 18, 1651-1661.
47. 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl. Med. Commun. 27, 371-376.
48. 99mTc- labeling of highly potent small peptides. Bioconjugate Chem. 8, 621-636.
49. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
50. Liu, S. (2004) The role of coordination chemistry in development of target-specific radiopharmaceuticals. Chem. Soc. Rev. 33, 1-18.
51. Edwards, D. S., Liu, S., Ziegler, M. C., Harris, A. R., Crocker, A. C., Heminway, S. J., and Barrett, J. A. (1999) RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide conjugated chemotactic peptide for infection imaging. Bioconjugate Chem. 10, 884-891.
52. m-labeled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits. Nucl. Med. Commun. 21, 1043-1051.
53. 4 receptor antagonist useful for imaging infection and inflammation. Bioconjugate Chem. 13, 881-886.
54. 99mTc-Labeling of a hydrazinonictotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjugate Chem. 12, 624-629.
55. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjugate Chem. 16, 1580-1588.
56. 99mTc-labeled cyclic RGDfK dimer. Bioconjugate Chem. 17, 1499-1507.
57. 3 expression. Bioconjugate Chem. 17, 1069-1076.
58. 3-positive breast cancer. Bioconjugate Chem. 18, 438-446.
59. 99mTc. Bioconjugate Chem. 8, 146-154.
60. Grady, E. F., Slice, L. W., Brant, W. O., Walsh, J. H., Payan, D. G., and Bunnett, N. W. (1995) Direct observation of endocytosis of gastrin releasing peptide and its receptor. J. Biol. Chem. 270, 4603-4611.
61. Slice, L. W., Yee, H. F., Jr., and Walsh, J. H. (1998) Visualization of internalization and recycling of the gastrin releasing peptide receptor-green fluorescent protein chimera expressed in epithelial cells. Receptors Channels 6, 201-212.
62. Coy, D. H., Mungan, Z., Rossowski, W. J., Cheng, B. L., Lin, J. T., Mrozinski, J. E., Jr., and Jensen, R. T. (1992) Development of a potent bombesin receptor antagonist with prolonged in vivo inhibitory activity on bombesin-stimulated amylase and protein release in the rat. Peptides 13, 775-781.